| 國家衛生研究院 |
2015-07 |
Gemcitabine plus cisplatin for advanced biliary tract cancer: A systematic review
|
Park, JO;Oh, DY;Hsu, C;Chen, JS;Chen, LT;Orlando, M;Kim, JS;Lim, HY |
| 臺大學術典藏 |
2022-08-19T00:20:46Z |
Gemcitabine plus cisplatin for advanced biliary tract cancer: A systematic review
|
Lim H.Y.; Kim J.S.; Orlando M.; Chen L.-T.; Chen J.-S.; CHIUN HSU; Oh D.-Y.; Park J.O. |
| 臺大學術典藏 |
2015 |
Gemcitabine plus cisplatin for advanced biliary tract cancer: A systematic review
|
Oh D.-Y.; Chiun Hsu; Chen J.-S.; Chen L.-T.; Orlando M.; Kim J.S.; Lim H.Y.; Park J.O.; Park J.O.;Oh D.-Y.;Chiun Hsu;Chen J.-S.;Chen L.-T.;Orlando M.;Kim J.S.;Lim H.Y. |
| 臺大學術典藏 |
2021-01-28T01:06:31Z |
Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: A multicenter prospective Phase II trial
|
Hsieh J.C.; Hsu C.-L.; Ng S.-H.; Wang C.-H.; Lee K.-D.; Lu C.-H.; Chang Y.-F.; Hsieh R.-K.; KUN-HUEI YEH; Hsiao C.-H.; Chen S.-Y.; Shiau C.-Y.; Wang H.-M. |
| 國家衛生研究院 |
2008-12 |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu, C;Kuo, SH;Hu, FC;Cheng, AL;Shih, JY;Yu, CJ;Lin, CC;Huang, TC;Yang, PC;Yang, CH |
| 臺大學術典藏 |
2022-08-19T00:21:07Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
CHIUN HSU; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
| 國立臺灣大學 |
2008 |
Gemcitabine Plus Conventional-Dose Epirubicin Versus Gemcitabine Plus Cisplatin as First-Line Chemotherapy for Stage Iiib/Iv Non-Small Cell Lung Carcinoma-a Randomized Phase Ii Trial
|
許駿; 郭頌鑫; 胡賦强; 鄭安理; 施金元; 余忠仁; 林家齊; 楊泮池; 楊志新; HSU, CHIUN; KUO, SUNG-HSIN; HU, FU-CHANG; CHENG, ANN-LII; SHIH, JIN-YUAN; YU, CHONG-JEN; LIN, CHIA-CHI; YANG, PAN-CHYR; YANG, CHIH-HSIN |
| 臺大學術典藏 |
2020-04-10T12:51:22Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Huang T.-C.; Yang P.-C.; Yang C.-H.; Lin C.-C.; Chiun Hsu; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2020-05-25T07:35:30Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C; Kuo S.-H; Hu F.-C; Cheng A.-L; Shih J.-Y; Yu C.-J; Chia-Chi Lin; Huang T.-C; Yang P.-C; Yang C.-H. |
| 臺大學術典藏 |
2020-05-26T09:27:21Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Lin C.-C; Huang T.-C; Yang P.-C; CHIH-HSIN YANG; Yu C.-J; Shih J.-Y; Cheng A.-L; Hu F.-C; Kuo S.-H; Hsu C; Chih-Hsin Yang;Yang P.-C;Huang T.-C;Lin C.-C;Yu C.-J;Shih J.-Y;Cheng A.-L;Hu F.-C;Kuo S.-H;Hsu C |
| 臺大學術典藏 |
2020-08-13T06:33:59Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Yang C.-H.; Yang P.-C.; Huang T.-C.; Lin C.-C.; Yu C.-J.; Hsu C.; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; JIN-YUAN SHIH |
| 臺大學術典藏 |
2020-12-02T02:34:30Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; PAN-CHYR YANG; Yang C.-H. |
| 臺大學術典藏 |
2021-02-23T08:26:37Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; SUNG-HSIN KUO; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:26Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; Kuo S.-H.; Hu F.-C.; ANN-LII CHENG; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2022-06-27T07:07:53Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; CHONG-JEN YU; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2018-09-10T06:52:59Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma—A randomized phase II trial
|
Chiun Hsu and Sung-Hsin Kuo and Fu-Chang Hu and Ann-Lii Cheng and Jin-Yuan Shih and Chong-Jen Yu and Chia-Chi Lin and Tsu-Chen Huang and Pan-Chyr Yang and Chih-Hsin Yang; Chong-Jen Yu; Sung-Hsin Kuo; JIN-YUAN SHIH; ANN-LII CHENG |
| 國家衛生研究院 |
2015-11 |
Gemcitabine synergistically enhances anti-tumor effects of recombinant immunogen-based cancer immunotherapy
|
Liu, SJ;Chang, LS;Yan, WL;Yeh, YC;Leng, CH |
| 國家衛生研究院 |
1997-05 |
Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study
|
Perng, RP; Chen, YM; MingLiu, J; Tsai, CM; Lin, WC; Yang, KY; WhangPeng, J |
| 臺大學術典藏 |
2021-02-23T08:26:35Z |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma
|
Yang S.-H.; Lin Z.-Z.; SUNG-HSIN KUO; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-10T03:53:07Z |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma
|
SHIH-HUNG YANG; Lin Z.-Z.; Kuo S.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-11T03:46:51Z |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma
|
Yang S.-H.; ZHONG-ZHE LIN; Kuo S.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-09-01T01:54:20Z |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma
|
Yang S.-H.; Lin Z.-Z.; Kuo S.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-12T04:01:31Z |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma
|
YANG SHIH-HUNG; Lin Z.-Z.; Kuo S.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-03-08T03:44:08Z |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma
|
SHIH-HUNG YANG; Lin Z.-Z.; Kuo S.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-06-10T06:11:13Z |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma
|
Yang S.-H.; ZHONG-ZHE LIN; Kuo S.-H.; Cheng A.-L. |
